After a decade of work, Otsuka and GW part ways on Sativex

A fizzled licensing agreement means GW will regain U.S. rights to its cannabinoid drug, which could be more of an albatross than a blessing.

By Jacob Bell • Dec. 13, 2017

Roche snaps up Huntington's drug on positive data

Benefits seen in a Phase 1/2a trial have spurred Roche to pick up its option for Ionis' antisense drug.

By Suzanne Elvidge • Dec. 13, 2017

Allergan picks up Repros to boost women's health offerings

A cheap uterine fibroid drug holds appeal to the specialty pharma. 

By Lisa LaMotta • Dec. 12, 2017

Ardelyx signs a Chinese commercialization deal for GI drug

Fosun is continuing its mission to bring biotech to a Chinese domestic market.

By Suzanne Elvidge • Dec. 12, 2017

Prescribed Reading: Dealmaking begins to pick up as 2018 approaches

It's been a slow year for deals, but it looks like Gilead's buy of Kite could be a catalyst for more M&A. 

By Lisa LaMotta • Dec. 8, 2017

Gilead deepens CAR-T push with deal for Cell Design

Fresh off acquiring Kite Pharma in August, Gilead will acquire Cell Design Labs and its engineering tech for up to $567 million. 

By Ned Pagliarulo • Dec. 7, 2017

Alexion taps Halozyme in platform deal worth $680M

Lured by the potential of Halozyme's drug-delivery technology, Alexion aims to develop subcutaneous formulations for some of its drug candidates. 

By Lisa LaMotta • Dec. 7, 2017

Arena strikes a partnership in Asia

The biotech has found a partner for its two lead drugs – Asia specialist Everest Medicines.

By Suzanne Elvidge • Dec. 5, 2017

J&J jumps in on Actelion spinout's hypertension drug

Through a collaboration deal, Idorsia is handing over rights to aprocitentan in exchange for a $230 million milestone payment.

By Jacob Bell • Dec. 4, 2017

Deal of the Year: Gilead Buys Kite Pharma

Faced with a waning hepatitis C business, Gilead finally came off the M&A sidelines to buy itself a leading position in CAR-T cell therapy. 

By Ned Pagliarulo • Dec. 4, 2017

The BioPharma Dive Awards for 2017

The 2017 BioPharma Dive Awards recognize the industry’s top innovators and disruptors. These executives, companies and trends are transforming the industry and shaping what's to come.

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • Dec. 4, 2017

Astellas picks up Mitobridge for rare mitochondrial diseases

By exercising its option, Astellas has snagged access to a clinical stage mitochondrial disease therapeutic.

By Suzanne Elvidge • Dec. 4, 2017

CVS Health to buy Aetna in $69B deal

The deal would combine CVS's retail pharmacy services with Aetna's health insurance business, creating a healthcare giant with significant market power.

By Jeff Byers , Shannon Muchmore • Dec. 3, 2017

Prescribed Reading: Industry CEOs talk PRVs, IPR, PCSK9

Leschly suggests PRVs should be an alternative source of revenue for biotechs; ear health R&D is all clogged up; and execs agree the IPR process should be thrown out. 

By Lisa LaMotta • Dec. 1, 2017

Medicines Co. sells infectious disease unit to put more money into PCSK9 drug

Pure-play antibiotics developer Melinta has agreed to acquire the unit for $270 million in guaranteed cash and equity.

By Jacob Bell • Nov. 29, 2017

AstraZeneca outlicenses Brilinta reversal agent

Though still preclinical, PB2452 could bolster the safety profile of AstraZeneca's blood thinner if it reaches the market.

By Jacob Bell • Nov. 28, 2017

How Anthem's new PBM will impact pharma

David Henka, CEO of RxTE Health, sat down with BioPharma Dive to discuss the implications of a new pharmacy benefit manager entering the marketplace. 

By Jacob Bell • Nov. 28, 2017

Biogen, Alkermes hook up on Tecfidera follow-on

Biogen is looking to limit competition to its blockbuster multiple sclerosis drug by buying into a follow-on version being developed by Alkermes. 

By Suzanne Elvidge • Nov. 28, 2017

BioMarin sells latest PRV for $125M

The biotech monetized its coveted priority review voucher, boosting its finances.

By Lisa LaMotta • Nov. 27, 2017

AMR Centre launches, announces new antimicrobial agreement

The launch of the AMR Centre at Alderley Park in the UK aims to fill the gap between basic research and the market for new antimicrobials.

By Suzanne Elvidge • Nov. 22, 2017

Prescribed Reading: FDA on approval streak, I/O shines

The regulatory agency granted seven approvals this week, including the first pill with a digital sensor, as well as the go-ahead for a new hemophilia drug. 

By Lisa LaMotta • Nov. 17, 2017

Merck strikes autoimmune deal with newly emerged Cue

The deal is right on cue, as the startup only emerged from stealth mode in January.

By Suzanne Elvidge • Nov. 17, 2017

Purdue pivots to oncology amidst opioid crisis

Better known for its prescription painkillers, the company has added four cancer drugs to its arsenal as backlash from the U.S. opioid epidemic intensifies.

By Suzanne Elvidge • Nov. 15, 2017

Loxo parlays cancer drug success into $1.5B deal with Bayer

The German drugmaker will pay $400 million upfront for partial rights to Loxo's rare cancer drug, lured by the promise of precision medicine.

By Ned Pagliarulo • Nov. 14, 2017

Zymeworks adds 6th pharma partner with J&J deal

The large pharma will pay $50 million upfront to gain access to Zymeworks' bispecific antibody platforms.

By Ned Pagliarulo • Nov. 13, 2017